Floatz logo

TIL

Solid Tumors, Adult

Grit BiotechnologyCell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

35 Active assets in the Solid Tumors, Adult cohort.

Asset / SponsorPhaseRating
Ribociclib
Eli Lilly and Company
Phase 1/2CC
Letrozole
Eli Lilly and Company
Phase 1/2CC
Zoladex
Eli Lilly and Company
Phase 1/2CC
Absk141-
Abbisko Therapeutics Co, Ltd
Phase 1/2CC
Epirubicin
Tango Therapeutics, Inc.
Phase 1/2CC

View all 38 →

Same molecule, other indications

TIL is also rated in:

cutaneous melanomaDormant
BBB
Indicative ·
72 / 100
View asset →
ovarian cancerDormant
BB
Indicative ·
70 / 100
View asset →
metastatic melanomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →